Blog

Explore how HUGO-Ab® and AbDrop™ accelerate fully human antibody discovery using microfluidics, high-throughput screening, and rapid lead optimization pipelines.

Antibody diagnostics like ELISA and lateral flow assays are essential tools. Biointron showcases their role in reliable disease detection and rapid clinical decisions.

Learn how antibody-dependent cellular phagocytosis targets cancer using monoclonal antibodies like rituximab, FcγR signaling, complement pathways and CD47-related resistance.

Antibody-drug conjugates unite antibody precision with cytotoxic potency. Biointron explains how ADCs deliver targeted therapies that revolutionize cancer treatment.

Antibody structure and dynamics drive therapeutic success. Biointron highlights how molecular insights improve stability, function, and performance of antibody drugs.

Therapeutic antibodies have transformed modern medicine. Biointron reviews their evolution, clinical applications, and impact on shaping today’s treatment landscape.

CHO cells are the gold standard for antibody production. Biointron applies codon optimization, advanced vectors, and stable expression systems to deliver high-yield recombinant antibodies.

Single B cell screening accelerates discovery. Biointron demonstrates how this technology identifies potent antibodies faster, guiding therapeutic development.

Epitope characterization shapes antibody science. Biointron outlines how mapping epitopes advances research, design, and development of therapeutic antibodies.

Understand antibody specificity and selectivity to improve research accuracy, and learn how high-affinity antibodies enhance target recognition while minimizing assay cross-reactivity.

Antibody research depends on sensitivity. Biointron explores how antigen quality and experimental conditions affect results and guide better antibody development.

Research-use-only biologics support discovery. Biointron explains how RUO materials fuel preclinical antibody development and enable reliable early-stage research.